Evidence map›Paper›PMID 17289815›Full record

ReviewBlood2007

New thrombopoietic growth factors.

David J Kuter

Registry-linked trialOpen access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Blood, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07093606 (Eltrombopag Induced Liver Dysfunction During Treatment of Immunethrombocytopenic Purpura), which is not on this map. Cited by 86 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
86citing papers in PubMed, 4 pooled it
16.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07093606 narecruitingnot on this mapstarted 2025, after this paper: background citation

Eltrombopag Induced Liver Dysfunction During Treatment of Immunethrombocytopenic Purpura

TypeinterventionalSponsorSohag UniversityRan2025 to 2026Enrolled100ConditionsITP - Immune ThrombocytopeniaArmsEltrombopag
3 · Its place in the literature

Who cites it

86 citing papers in PubMed, 4 syntheses or guidelines pooled it, 306 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Thrombopoietin mimetics for patients with myelodysplastic syndromes.The Cochrane database of systematic reviews · 2017
    Pooled it
  4. TPO receptor agonist for chronic idiopathic thrombocytopenic purpura.The Cochrane database of systematic reviews · 2011
    Pooled it
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Observational
  11. Review
  12. Article
  13. Observational
  14. Article
  15. Avatrombopag for the Treatment of Immune Thrombocytopenia.European journal of haematology · 2025
    Review
  16. Article
  17. Review
  18. Article
  19. Review
  20. Article

26 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

David J KuterHematology Division, Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114, USA. kuter.david@MGH.harvard.edu
Massachusetts General Hospital · US

Funding

Proteogenomic Analysis of Platelets in ThrombocythemiaR01HL082889 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI KUTER, DAVID J · 2005 to 2008
$2.3M
Studies of rHuTPO in ITP and of rVlla in Liver DiseaseU01HL072299 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI KUTER, DAVID J · 2002 to 2012
$1.6M
NHLBI NIH HHS HL 72299NHLBI NIH HHS HL 82889NHLBI NIH HHS R01 HL082889NHLBI NIH HHS U01 HL072299
6 · The paper itself

Abstract

Although development of first-generation thrombopoietic growth factors (recombinant human thrombopoietin [TPO] and pegylated recombinant human megakaryocyte growth and development factor [PEG-rHuMGDF]) was stopped due to development of antibodies to PEG-rHuMGDF, nonimmunogenic second-generation thrombopoietic growth factors with unique pharmacologic properties have been developed. TPO peptide mimetics contain TPO receptor-activating peptides inserted into complementarity-determining regions of Fab (Fab 59), attached to the IgG Fc region (AMG 531), or pegylated (Peg-TPOmp). Orally available, TPO nonpeptide mimetics (eltrombopag, AKR-501) bind and activate the TPO receptor by a mechanism different from TPO and may have an additive effect to TPO. TPO agonist antibodies are monoclonal antibodies activating the TPO receptor but modified in size [TPO minibodies; ie, VB22B sc(Fv)(2)] or immunoglobuln type (domain subclass-converted TPO agonist antibodies; ie, MA01G4G344). All second-generation thrombopoietic growth factors stimulate growth of TPO-dependent cell lines via JAK2/STAT signaling pathways and increase platelet counts in animals. When tested in healthy humans, TPO peptide and nonpeptide mimetics produced a dose-dependent rise in platelet count. AMG 531 and eltrombopag markedly increase platelet counts in patients with immune thrombocytopenic purpura, without significant adverse effects. One or more second-generation thrombopoietic growth factors should soon be clinically available for treating thrombocytopenic disorders.

Indexed as

Chemistry, PharmaceuticalDrug DesignHumansIntercellular Signaling Peptides and ProteinsModels, BiologicalModels, ChemicalPeptidesPolyethylene GlycolsSignal TransductionThrombopoiesisThrombopoietinIntercellular Signaling Peptides and ProteinsPeptidesPolyethylene GlycolsThrombopoietin

Identifiers

PMID17289815
PMCPMC1885525
OpenAlexW4244215862

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.